research Isotretinoin treatment for folliculitis decalvans: a retrospective case‐series study
Oral isotretinoin, especially at higher doses for at least 3 months, is effective for treating folliculitis decalvans.
Search
for
Sort by
Research
810-840 / 1000+ results
research UTILIZAÇÃO DE ISOTRETINOÍNA ORAL NO TRATAMENTO DA ALOPECIA FIBROSANTE FRONTAL: SÉRIE DE CASOS
Oral isotretinoína effectively stabilizes frontal fibrosing alopecia.
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research BH06: Clinical trial of combination therapy with oral hydroxychloroquine and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia
research Prognosis, treatment, and disease outcomes in frontal fibrosing alopecia: A retrospective review of 92 cases
Most patients with frontal fibrosing alopecia stabilized with treatment, especially younger ones, using intralesional corticosteroids and tacrolimus.
research Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report
Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
research Acne Keloidalis Nuchae Successfully Treated with Halobetasol 0.01% and Tazarotene 0.045% Lotion
A new lotion with halobetasol and tazarotene successfully treats acne keloidalis nuchae.
research Upadacitinib for the treatment of alopecia areata – A case report
Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
research Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau
Etanercept effectively treated a severe skin condition when other treatments failed.
research Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
Baricitinib can cause excessive hair growth.
research JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
research Efficacy and Safety of Combination of Mometasone Furoate 0.1% Cream and Adapalene 0.1% Gel in Alopecia Areata
The treatment is effective for mild alopecia areata but often causes mild side effects.
research Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double‐blind placebo‐controlled trial
The new clobetasol propionate foam is effective and safe for treating alopecia areata.
research Common Topical Medications
The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research Baricitinib for the Treatment of Moderate-to-Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
research Microneedling Plus Clobetasol Propionate 0.05% Cream versus Clobetasol Propionate 0.05% Cream Alone in the Treatment of Alopecia Areata
Microneedling with clobetasol cream works better for hair regrowth in alopecia areata than clobetasol cream alone.
research Topical Administration of 15‐Deoxy‐Δ12,14‐Prostaglandin J2 Using a Nonionic Cream: Effect on UVB‐Induced Skin Oxidative, Inflammatory, and Histopathological Modifications in Mice
15d‐PGJ2 cream protects against UVB-induced skin damage in mice.
research Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
Dabrafenib can cause skin growths and sometimes low-grade skin cancer.
research Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.
research Tralokinumab as a therapeutic option for patients with concurrent atopic dermatitis and alopecia areata
research Comparison of Systemic Mycophenolate Mofetil with Topical Clobetasol in Lichen Planopilaris: A Parallel-Group, Assessor- and Analyst-Blinded, Randomized Controlled Trial
Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
research A rare case of multiple keratoacanthomas treated with oral acitretin and intralesional methotrexate
A 25-year-old man with multiple skin tumors was successfully treated with acitretin and methotrexate.
research A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and Opuntia ficus-indica Extract Versus Calcipotriol/Betamethasone in Adult Patients with Mild-to-moderate Psoriasis.
The cream with xyloglucan, pea protein, and cactus extract works as well as the standard treatment for psoriasis and is well-tolerated.
research Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
Ritlecitinib is effective and safe for treating severe alopecia areata in people aged 12 and older.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.
research In vivo microautoradiography of [3H]1,24(OH)2D3 (tacalcitol) following topical application to normal rats and in vitro metabolism in human keratinocytes
Topical tacalcitol can treat psoriasis by acting directly on skin cells.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.